Goodwill And Intangible Assets (Narrative) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended			9 Months Ended
	Sep. 30, 2012	Mar. 31, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Intangible Assets Excluding Goodwill [Line Items]
Amortization expense				$ 304.7	$ 273.0
Expected amortization expense, remainder of 2012	86			86
Expected amortization expense, 2013	342			342
Expected amortization expense, 2014	335			335
Expected amortization expense, 2015	312			312
Expected amortization expense, 2016	245			245
Impairment charge related to in-process research and development	41.6		16.2
Acquired in-process research and development assets reclassified to product rights and licenses				33.0
Product rights and license costs acquired		$ 70.0
Number of dermatological products acquired from Valeant Pharmaceuticals		2
In-Process Research and Development
Intangible Assets Excluding Goodwill [Line Items]
Rate used to discount net cash inflows to present values	10.00%		10.00%